MedTrace Logo

Percutaneous High-dose Radiotherapy in Patients With Oligometastases of Prostate Carcinoma

NCT02264379 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2023-02-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the outcomes of patients treated with an high dose radiation regimen using either stereotactic hypofractionated or normofractionated radiotherapy for oligometastatic prostate cancer and to establish efficacy (producing a desired result or effect) and safety in this setting.

Conditions

Interventions

RADIATION

normal fractionated irradiation

25\*2 Gy (once a day, 5 days a week)

RADIATION

hypo fractionated irradiation

3\*10 Gy (once a day, 2-3 days a week)

Sponsors & Collaborators

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Tobias Hölscher, Dr. · Technische Universität Dresden, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2020-10-31
Completion
2021-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02264379 on ClinicalTrials.gov